Search results
Results from the WOW.Com Content Network
Temsirolimus, sold under the brand name Torisel, is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in May 2007, [3] and was also approved by the European Medicines Agency (EMA) in November 2007. [1]
In the European Union, the European Medicines Agency has jurisdiction and the relevant documents are called the "summary of product characteristics" (SPC or SmPC) and the document for end-users is called the "patient information leaflet" or "package leaflet". The SPC is not intended to give general advice about treatment of a condition but does ...
Usually cancer drugs go after patients with no other options first before moving on to a first-line indication, so it's curious that Pfizer's (NYS: PFE) Torisel, which is approved as a first-line ...
mTOR inhibitors are a class of drugs used to treat several human diseases, including cancer, autoimmune diseases, and neurodegeneration. They function by inhibiting the mammalian target of rapamycin (mTOR) (also known as the mechanistic target of rapamycin), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases ...
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. [2] It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) in January 2006.
Patients and their diseases are profiled in order to identify the most effective treatment for their specific case. Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, [1] others being hormonal therapy and cytotoxic chemotherapy.
Each antibody binds only one specific antigen. Monoclonal antibodies (mAbs) have varied therapeutic uses. It is possible to create a mAb that binds specifically to almost any extracellular target, such as cell surface proteins and cytokines.
The Semirara Mining and Power Corporation (SMPC) is a mining company based in the Philippines. The company, a subsidiary of DMCI Holdings , operates its main coal mine in Semirara Island and is the biggest coal producer in the Philippines accounting for 92 percent of the total national production as of 2015.